Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1 -associated Parkinson’s disease
Human Molecular Genetics · 18.05.2023 · 32 (11) · 1888-1900
DOI: 10.1093/hmg/ddad025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, online erschienen am 08.02.2023. Verfasst von Manoj Kumar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Induced Pluripotent Stem Cells, Gaucher Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bi-allelic mutations in GBA1, the gene that encodes β-glucocerebrosidase (GCase), cause Gaucher disease (GD), whereas mono-allelic mutations do not cause overt pathology. Yet mono- or bi-allelic GBA1 mutations are the highest known risk factor for Parkinson’s disease (PD). GCase deficiency results in the accumulation of glucosylceramide (GluCer) and its deacylated metabolite glucosylsphingosine (GluSph). Brains from patients with neuronopathic GD have high levels of GluSph, and elevation of this lipid in GBA1-associated PD has been reported. To uncover the mechanisms involved in GBA1-associated PD, we used human induced pluripotent stem cell-derived dopaminergic (DA) neurons from patients harboring heterozygote mutations in GBA1 (GBA1/PD–DA neurons). We found that compared with gene-edited isogenic controls, GBA1/PD–DA neurons exhibit mammalian target of rapamycin complex 1 (mTORC1) hyperactivity, a block in autophagy, an increase in the levels of phosphorylated α-synuclein (129) and α-synuclein aggregation. These alterations were prevented by incubation with mTOR inhibitors. Inhibition of acid ceramidase, the lysosomal enzyme that deacylates GluCer to GluSph, prevented mTOR hyperactivity, restored autophagic flux and lowered α-synuclein levels, suggesting that GluSph was responsible for these alterations. Incubation of gene-edited wild type (WT) controls with exogenous GluSph recapitulated the mTOR/α-synuclein abnormalities of GBA1/PD neurons, and these phenotypic alterations were prevented when GluSph treatment was in the presence of mTOR inhibitors. We conclude that GluSph causes an aberrant activation of mTORC1, suppressing normal lysosomal functions, including the clearance of pathogenic α-synuclein species. Our results implicate acid ceramidase in the pathogenesis of GBA1-associated PD, suggesting that this enzyme is a potential therapeutic target for treating synucleinopathies caused by GCase deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- German Center for Neurodegenerative Diseases (DZNE), Tübingen 72076, Germany.
- Neuroregeneration Research Institute, Harvard Medical School/McLean Hospital, Belmont, MA 02478, USA.
ORCID-Profile: Ricardo A Feldman
Zitieren
APA
Kumar, M., Srikanth, M. P., Deleidi, M., Hallett, P. J., Isacson, O., & Feldman, R. A. (2023). Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1 -associated Parkinson’s disease. Human Molecular Genetics, 32(11), 1888-1900. https://doi.org/10.1093/hmg/ddad025
Vancouver
Kumar M, Srikanth MP, Deleidi M, Hallett PJ, Isacson O, Feldman RA. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1 -associated Parkinson’s disease. Human Molecular Genetics. 2023;32(11):1888-1900. doi:10.1093/hmg/ddad025
BibTeX
@article{Kumar2023,
author = {Kumar, Manoj and Srikanth, Manasa P and Deleidi, Michela and Hallett, Penelope J and Isacson, Ole and Feldman, Ricardo A},
title = {Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1 -associated Parkinson’s disease},
journal = {Human Molecular Genetics},
year = {2023},
volume = {32},
number = {11},
pages = {1888--1900},
doi = {10.1093/hmg/ddad025}
}
EUVIMED